A randomized controlled trial for Wenyang Sanjie Decoction in the treatment of bone metastasis of lung cancer
- Conditions
- bone metastasis of lung cancer
- Registration Number
- ITMCTR2000003688
- Lead Sponsor
- onghua Hospital, Shanghai University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) Patients with primary lung cancer confirmed by cytological or histopathological methods and confirmed by X-ray, CT, MRI, bone ECT, PET/CT and other imaging examinations;
(2) TCM syndrome differentiation is Yangxu Tanning;
(3) Patients with bone metastasis who could not receive chemoradiotherapy within 1 month, or over 1 month after the end of chemoradiotherapy;
(4) Aged > 18 years and <= 75 years;
(5) Karnofsky score >= 60, life expectancy >= 6 months;
(6) Allergic to traditional Chinese medicine, zoledronic acid and topical ointment;
(7) Understand and agree to receive the treatment, and sign the informed consent.
(1) Pain accompanied by local redness, swelling and fever;
(2) Those who apply targeted drug therapy;
(3) Patients with severe heart, liver and kidney diseases or a history of mental illness;
(4) Poor compliance and incomplete data;
(5) Persons with a history of mental illness.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bone metastases change;
- Secondary Outcome Measures
Name Time Method The quality of life;Progression-free survival;Serum calcium;The degree of pain;Tumor marker;The immune function;Alkaline phosphatase;